Medmen Entprs B Sub Vtg

Good day and thank you for standing by. Welcome to the MedMen first quarter fiscal 2022 earnings call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question and answer session. To ask a question during that session, you will need to press star 1 on your telephone. Please be advised that today's call is being recorded. If you require any further assistance during the call, please press star zero. I would now like to hand the conference over to your speaker today, Mr. Reeves Fulcham, Chief Financial Officer.

Thank you. Good afternoon and welcome, everyone. Today, I am joined by our CEO, Tom Lynch, and Chief Revenue Officer, Tracy McCourt. on today's call management will provide prepared remarks and then we will open the call to your questions earlier today we issued a press release announcing first quarter fiscal 2022 results for the period ending september 25th 2021 the press release along with our financial statements and mdna are available on the company's website and files on both edgar and sadar before we begin I'd like to remind you that the comments on today's call will include forward-looking statements, which by their nature involve estimates, projections, goals, forecasts, and assumptions, and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Forward-looking statements relate to, among other things, the business and operations of MedMen, our plans for new stores, our financial, operational, and strategic expectations, and our expectations as to the future sources of funding. These forward-looking statements speak only as of the date of this conference call and should not be relied upon as predictions of future events. Additional information about the material factors and assumptions forming the basis of the forward-looking statements and risk factors are provided in the press release and in the company's reports filed with the United States Securities and Exchange Commission and Canadian securities regulators. During today's conference call, MedMin will refer to certain non-GAAP measures that do not have any standardized meaning prescribed by GAAP, such as EBITDA, retail-adjusted EBITDA, and corporate SG&A, which are defined in the earnings press release we issued earlier today. Reconciliations to GAAP measures are contained in the press release. Please note, all financial information is provided in U.S. dollars unless otherwise indicated. Now, with that, I'd like to turn the call over to Tom.

Thank you, everyone, for joining us this afternoon where we will provide another update on the company's turnaround progress including execution on our transition to growth and plans to drive future growth, as well as our financial performance for the first quarter of 2022. The past quarter, we were able to deliver solid year-over-year revenue growth despite a softening in the overall macro environment quarter-over-quarter. During the fiscal quarter, increased COVID cases associated with the Delta variant and a reduction in government assistance helped drive a sequential deceleration in cannabis sales across the majority of the states we operate in. I'm pleased to say that MedMen's results held up well in this environment. Based on data from Headset, we outperformed state-level market revenue data on a year-over-year basis in California, Nevada, and Arizona. And for the states where we have market data, Illinois was the only state where we lagged the market revenue trends. Let's review the highlights from Q1. Quarterly revenue for MedMen came in at $39.8 million, up 13.4% from a year ago. The sales increase was driven by frequency of transactions and greater traffic and was broad-based, with all states other than Illinois posting positive year-over-year sales growth. Sequentially, total revenue came down 5.1% below the previous quarter, reflecting some of the shifts in the macro environment I mentioned. We posted our fifth consecutive quarter of positive retail EBITDA, which came in at 6.7 million for the quarter, up 29.3% year over year. We did see a sequential softening from last quarter's 8.9 million of retail EBITDA. This was largely attributable to lower gross margins. The gross margin decline primarily reflects a more intense promotional environment during the quarter. which we believe was exacerbated by the sequential softening in the macro sales environment. On the expense side, corporate SG&A, excluding pre-opening costs, increased 42.6% year-over-year to 14.6 million. This was largely driven by a 3.9 million increase year-over-year in professional fees, primarily as a result of litigation costs associated with previous officers of the company. Excluding the impact of the higher litigation costs, the year-over-year increase in corporate SG&A would have been 4.6%. As a reminder, at its peak, the company's corporate SG&A was approximately $160 million annually, meaning even with some elevated legal expenses during this quarter, we have still taken out $100 million in annualized expenses. We made two other recent announcements I would also like to mention. The first is the promotion of Roz Litzy to the role of Chief Operating Officer. Roz brings 25 years of operational experience, focusing on business startup, scaling, and strategy. She has a deep understanding of the MedMen business, and her skills will be invaluable in our new phase of growth and momentum. I'd like to thank Tim Bossidy for the critical role he played in the implementation and acceleration of MedMen's turnaround plans. Tim is returning to Sierra Constellation Partners and has left MedMen well positioned to remain focused on profitability, expanding to new markets, and delivering the industry's premier retail experience. We also recently announced an agreement with Lidhouse Farms to manage cultivation and manufacturing at our facilities in Desert Hot Springs, California, and Sparks, Nevada. Lidhouse is one of the most highly awarded cultivators in California, and we're excited to partner with them. We're excited about our growth prospects ahead, with a number of new store openings planned in key markets. We recently opened stores in Orlando and Tallahassee, with more new stores to come in Florida. We plan to open two new stores in California over the next six months, along with two openings in Massachusetts and one in Illinois. As revenue from these new stores comes online, we expect continued progress on profitability metrics. As noted in our fiscal year-end call back in September, we have drastically improved our expense structure, generated momentum in quarterly sales from a year ago, and have now posted a positive retail adjusted EBITDA for five consecutive quarters. Looking ahead, we plan to accelerate our growth and push towards company-wide profitability in the coming quarters. As we leverage our national brand recognition to drive new store growth in Florida, California, Massachusetts, Arizona, and Illinois. We appreciate the patience and support from our stakeholders as we executed the key elements of our turnaround plan. We could not be more excited to execute on our growth plan and deliver the revenue and profitability numbers we believe this brand is capable of generating. With that, I will hand it over to Tracy McCourt, our Chief Revenue Officer for Marketing and Operations Highlights from the quarter.